Senseonics (NYSE:SENS) Reaches New 12-Month High - Time to Buy?

Senseonics Holdings, Inc. (NYSE:SENS - Get Free Report)'s stock price hit a new 52-week high on Wednesday . The company traded as high as $0.95 and last traded at $0.99, with a volume of 3044314 shares trading hands. The stock had previously closed at $0.91.

Analyst Upgrades and Downgrades

SENS has been the subject of a number of recent analyst reports. HC Wainwright restated a "buy" rating and issued a $2.00 price objective on shares of Senseonics in a research report on Friday, November 15th. StockNews.com assumed coverage on Senseonics in a research report on Thursday, December 26th. They set a "sell" rating on the stock.

Senseonics Trading Up 8.3 %

The company has a market cap of $583.48 million, a P/E ratio of -7.54 and a beta of 0.64. The business's 50-day moving average price is $0.47 and its 200 day moving average price is $0.41. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47.

Senseonics (NYSE:SENS - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.01). The company had revenue of $4.26 million during the quarter, compared to the consensus estimate of $4.02 million. Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. As a group, analysts expect that Senseonics Holdings, Inc. will post -0.14 earnings per share for the current year.

Remove Ads

Insiders Place Their Bets

In other Senseonics news, CFO Frederick T. Sullivan acquired 124,933 shares of Senseonics stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $0.38 per share, with a total value of $47,474.54. Following the completion of the purchase, the chief financial officer now directly owns 2,478,844 shares of the company's stock, valued at $941,960.72. This represents a 5.31 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Timothy T. Goodnow bought 315,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were acquired at an average cost of $0.31 per share, with a total value of $97,650.00. Following the purchase, the chief executive officer now owns 11,310,355 shares of the company's stock, valued at approximately $3,506,210.05. This represents a 2.86 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company's stock.

Institutional Investors Weigh In On Senseonics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Ridgecrest Wealth Partners LLC acquired a new position in Senseonics in the 4th quarter valued at approximately $60,000. Geode Capital Management LLC grew its stake in shares of Senseonics by 3.2% in the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company's stock worth $2,042,000 after purchasing an additional 179,103 shares during the last quarter. FMR LLC increased its holdings in Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company's stock valued at $59,000 after purchasing an additional 167,970 shares during the period. GSA Capital Partners LLP bought a new position in Senseonics during the 3rd quarter worth $117,000. Finally, Symmetry Partners LLC acquired a new position in Senseonics during the 3rd quarter worth about $164,000. Institutional investors own 12.36% of the company's stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.